MEDIWOUND LTD IS-,01 (M8W.BE)
| Previous close | 15.60 |
| Open | 15.50 |
| Bid | 15.20 x N/A |
| Ask | 15.90 x N/A |
| Day's range | 15.50 - 15.50 |
| 52-week range | 12.10 - 17.90 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 13 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
MediWound Ltd. ( NASDAQ:MDWD ) last week reported its latest quarterly results, which makes it a good time for...
ZacksMediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of 2.50% and 6.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireMediWound Reports First Quarter 2024 Financial Results and Provides Company Update
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time YAVNE, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first
